alexa High Serum Procalcitonin: Interpret with Caution | Open Access Journals
ISSN: 2327-5073
Clinical Microbiology: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

High Serum Procalcitonin: Interpret with Caution

Fahmi Yousef Khan*

Department of Medicine, Hamad General Hospital, P.O. Box 3050, Doha, Qatar

*Corresponding Author:
Khan FY
Consultant, Department of Medicine
Hamad General Hospital, P.O. Box: 3050
Doha, Qatar
Tel: 0974-55275989
Fax: 0974-44321276
E-mail: [email protected]

Received date: April 27, 2017; Accepted date: April 28, 2017; Published date: April 29, 2017

Citation: Khan FY (2017) High Serum Procalcitonin: Interpret with Caution. Clin Microbiol 6:e141. doi:10.4172/2327-5073.1000e141

Copyright: © 2017 Khan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Clinical Microbiology: Open Access

Editorial

Serum procalcitonin (PCT), which is usually produced in thyroid Ccells, is a precursor of calcitonin. In general, PCT is not released into the blood and, therefore, cannot be detected in healthy individuals [1]. However, serum procalcitonin increased significantly in response to stimulation by bacterial infections showing a favorable pharmacokinetic profile as clinical markers for bacterial infection. Consequently PCT has been used increasingly to identify systemic bacterial infections since mid of 1990 [2]. Moreover, a growing body of evidence has suggested that high serum PCT is a useful biochemical marker for discriminating between sepsis and some non-infectious causes of systemic inflammatory response syndrome and is a valuable prognostic marker [3]. A rise or no change in procalcitonin level in second week was a good predictor of outcome suggesting intensification of antibiotic therapy [2]. Recent randomized clinical trials showed that serum PCT level can be used to guide antibiotic therapy in patients with severe sepsis; it resulted in a significant reduction of antibiotic therapy and similar medical outcomes. In addition, the length of intensive care treatment in the PCT-guided group was significantly shorter than that in the control group [4,5]. In febrile neutropenia, PCT was found to be useful in diagnosing bacterial infection in these patients [6]. Noteworthy, most of the above mentioned clinical implications of PCT were derived from observational studies.

Despite these growing evidences, elevation of serum PCT continues to challenge the diagnostic acumen of physicians as more recent studies have produced conflicting results [7]. Additionally, usefulness of PCT measurement in sepsis confirmation has some limitations such as false-positive and false-negative results; some patients with sepsis may not have increased PCT levels while others with high serum PCT may not have sepsis. According to available evidences, elevation in serum PCT levels in the absence of a bacterial infection can be seen in situations of massive stress, for example after severe trauma and surgery, in patients after cardiac shock or some autoimmune diseases such as Kawasaki disease and adult-onset Still’s disease [2]. Procalcitonin also may be elevated in medullary thyroid cancer, small cell lung cancer, postoperative complications, cirrhosis, pancreatitis, ischemic bowel and paraneoplastic syndrome [8,9]. Conversely, high PCT levels may not be found in patients with mycoplasma community acquired pneumonia and in patients who received antibiotic pretreatment [5]. Second limitation is that there is no single cut-off range of PCT levels for defining sepsis. While for some types of infections and clinical settings optimal PCT cut-offs have been established, optimal cut-off levels for other infections have not been established yet. Thus, the clinical benefit and safety of using serum PCT level in different clinical settings remains undefined. Third limitation is related to the efficacy of PCT level monitoring as guidance for antibiotic therapy. This property has been tested for certain infections such as respiratory tract infections and is not applicable to other infections.

In view of available evidences it is too early to come up with final conclusions on the efficacy of PCT in diagnosing sepsis or other related situations. Therefore, high serum PCT level should be interpreted with caution; physicians should incorporate this biomarker with medical context of the disease and other tests related to infection when diagnosing sepsis.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 127
  • [From(publication date):
    April-2017 - May 23, 2017]
  • Breakdown by view type
  • HTML page views : 105
  • PDF downloads :22
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version